Vinson & Elkins advised Lexicon Pharmaceuticals, while Simpson Thacher represented Invus on the deal. Cooley represented the underwriters for the public offering.Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)…
Lexicon Pharmaceuticals’ $143.7 Million Common Stock Offering
